$60 Billion AI Drug Discovery — Why ZERO FDA Approvals part3 #viral #viralvideo #shorts

💊 $60 Billion AI Drug Discovery — Why ZERO FDA Approvals?part3

AI-driven drug discovery has attracted over $60 billion in investment since 2015, leading to the rise of more than 800 companies promising faster, cheaper, and more effective medicines; however, despite this massive momentum, not a single fully AI-discovered drug has yet received approval from the U.S. Food and Drug Administration, highlighting a significant gap between hype and reality. The core challenge lies in the complexity of human biology, which is far more than patterns in data—biological systems are highly context-dependent, nonlinear, and still not fully understood, making it difficult for AI models to translate predictions into real-world therapeutic success. Early AI approaches also suffered from the “black box” problem, where models could suggest promising molecules without clearly explaining their mechanisms of action, a critical requirement for regulatory approval. Furthermore, even the most promising AI-generated candidates must undergo rigorous clinical trials involving safety, efficacy, and large-scale validation in humans, a process that typically takes 10–15 years and remains a major bottleneck regardless of technological advancements. Another limitation is data quality, as AI systems depend heavily on available biological and chemical datasets, which are often incomplete, biased, or lacking sufficient depth to capture true disease complexity. Despite these challenges, the field is evolving rapidly with breakthroughs like AlphaFold 3, which are shifting the focus from simple prediction to deeper biological understanding and generative design, enabling scientists to model molecular interactions with unprecedented accuracy. This marks a transition from early “Tier 1” AI systems focused on pattern recognition to more advanced “Tier 2” approaches that integrate mechanistic insights and generative capabilities. As a result, the future of AI in drug discovery is not one of failure but of maturation, where the first successful approvals are likely to come from hybrid pipelines that combine AI with traditional experimental validation rather than fully autonomous systems. Ultimately, while AI will not eliminate the inherent complexity of biology or the need for rigorous testing, it is poised to significantly enhance and accelerate the drug discovery process over time.

#shortsfeed #shortvideo #shortfeed #shorts #viral #viralvideo #ytshorts #trending
#aidrugdiscovery #artificialintelligence #pharmatech #biotech #futureofmedicine #healthcareinnovation #drugdiscovery #airevolution #medicalbreakthrough #deeptech #aiinhealthcare #startupecosystem #techpodcast #sciencepodcast #innovationtalks #clinicaltrials #alphafold3 #pharmaindustry #digitalhealth #aitrends #trending #medtech #futuretech #hypevsreality #scienceexplained #viral #viralvideo #youtube #facelessyoutube #DrAmaravadhiH

AI drug discovery, why no FDA approved AI drugs, AI in pharma 2026, AlphaFold 3 explained, biotech AI startups, drug discovery challenges, clinical trials bottleneck, AI in healthcare future, pharmaceutical innovation, AI vs traditional drug discovery, black box AI problem pharma, generative AI drug design, deep learning drug discovery, AI pharma investment 60 billion, biotech trends 2026

Видео $60 Billion AI Drug Discovery — Why ZERO FDA Approvals part3 #viral #viralvideo #shorts канала Dr Amaravadhi H